The settlement resolves a government investigation into Mallinckrodt’s subsidiary Questcor, which it acquired for about $5.6 billion in 2014. The settlement covers charges related to an investigation of Questcor’s sales and marketing techniques, but does not resolve allegations involving its charitable foundation’s activities.
Mallinckrodt did not admit any wrongdoing. Terms of the agreement have not been finalized.
Read the full news release here.
More articles on pharmacy:
Viewpoint: The $2.1M drug price record won’t last long
Purdue Pharma hit with 4 more opioid lawsuits: 4 things to know
EpiPen shortage will drag on: 4 things to know
